A new direct-to-patient portal called LillyDirect by Eli Lilly will allow patients to obtain anti-obesity medications for as little as $25 a month. This is seen as a major shift in medication accessibility for those struggling with obesity. There are also improvements in insurance coverage for these medications, and new research reveals the benefits of semaglutide (Wegovy) in reducing the risk of cardiovascular events in those with obesity and preexisting cardiovascular disease. Concerns have been raised about direct-to-consumer services and the need for transparency to avoid conflicts of interest. It is important for insurance companies to cover obesity medications, as they have been shown to be beneficial for patients.
Source link
Eli Lilly Offers Obesity Drug Directly to Consumers
